Literature DB >> 19465682

Genetic aspects of familial thyroid cancer.

Patrick J Morrison1, A Brew Atkinson.   

Abstract

Familial thyroid cancer is rare, accounting for <10% of thyroid cancer cases. Activating germline point mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia types 2A, 2B, and familial medullary thyroid cancer (FMTC)-around 3% of thyroid cancer cases. Familial papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) have been identified as a distinct group of familial thyroid cancers. Sporadic nonmedullary thyroid cancer (NMTC) accounts for approximately 90% of all thyroid cancers-about 6% of NMTCs are familial (FNMTC). Although multiple endocrine neoplasia types 2A and 2B and FMTC are well characterized, very little is known about the genetic predisposition to PTC and FTC. In this paper, the genetic types of FMTC and FNMTC are reviewed and the clinical features and screening are outlined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465682     DOI: 10.1634/theoncologist.2009-0046

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  10 in total

Review 1.  Familial pediatric endocrine tumors.

Authors:  Sarinda Millar; Lisa Bradley; Deirdre E Donnelly; Dennis Carson; Patrick J Morrison
Journal:  Oncologist       Date:  2011-09-20

2.  Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.

Authors:  X-P Qi; R-B Ying; J-M Ma; W-T Liu; Z-F Du; J Fei; C-P Yang; Q-Z Song; H-Y Jin; Z-G Chen; J-S Han; J-Q Wang; X-L Chen; Y Zhao; J-J Lu; X-N Zhang
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

Review 3.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

4.  Epidemiology, clinical features, and genetics of multiple endocrine neoplasia type 2B in a complete population.

Authors:  Anna Znaczko; Deirdre E Donnelly; Patrick J Morrison
Journal:  Oncologist       Date:  2014-10-29

Review 5.  Advances in the genetics of familial renal cancer.

Authors:  Patrick J Morrison; Deirdre E Donnelly; A Brew Atkinson; Alexander P Maxwell
Journal:  Oncologist       Date:  2010-05-19

6.  Sdhd ablation promotes thyroid tumorigenesis by inducing a stem-like phenotype.

Authors:  Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista La Perle; Xiaoli Zhang; José I Piruat; José López-Barneo; Sissy M Jhiang; Lawrence S Kirschner
Journal:  Endocr Relat Cancer       Date:  2017-09-19       Impact factor: 5.678

7.  RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma.

Authors:  Sisi Wang; Bo Wang; Chao Xie; Daoxiong Ye
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

8.  Genetic Association of XRCC1 Gene rs1799782, rs25487 and rs25489 Polymorphisms with Risk of Thyroid Cancer: a Systematic Review and Meta-Analysis

Authors:  Jamal Jafari Nedooshan; Mohammad Forat Yazdi; Hossein Neamatzadeh; Masoud Zare Shehneh; Saeed Kargar; Niloofar Seddighi
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

9.  Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline.

Authors:  Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze
Journal:  Endocr Relat Cancer       Date:  2022-09-07       Impact factor: 5.900

10.  Familial multinodular goiter syndrome with papillary thyroid carcinomas: mutational analysis of the associated genes in 5 cases from 1 Chinese family.

Authors:  Shunyao Liao; Wenzhong Song; Yunqiang Liu; Shaoping Deng; Yaming Liang; Zhenlin Tang; Jiyuan Huang; Dandan Dong; Gang Xu
Journal:  BMC Endocr Disord       Date:  2013-10-21       Impact factor: 2.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.